ul

 

 

 

INBIFO Institut far biologische Forschung GmbH - K6in

 

Report P 0500/3237 9710/9 Page i
Contents Page
1 ADSHIACE...... ee ceccccececsecneceeeceteecneeecenseanesersesersneesesseseaecsetsesterseeseatens 1
2 ODIO CHIVE eect eee eter raeereaeeteetene renee senascasaenesteeepaneseeetenneeeses 2
3 General Design
4 Test Substance

 

 
 

 

 

 

41 Research Cigarettes ......ccccsseesssseenssssessserenseserseeessssnesaunesssssescnsseccerseetevseereesensees 3
4.2 TPM Preparation, Dosing, and Analyses... ececsseseeneesteecaepeacecetaceaseenresseeceetees 4
5 Experimental Design and Procedures... eeesesseeeseeteeeteeneete 6
5.1 Media and Reagent Preparation oo... seseceessenerensnecesseseessesssneacsenecesenenseseeeneasens 6
5.2 Test System and Procedure... ccc cassecsscceesssseenesssceesssecemsetesasecerecnesesesseneeeeeeeenerees 7
§.3 Test System Characterization and Criteria for Test Validity 0... cette cesteeseenens 9
6 Statistics and Evaluations .........ccccsccsssseseesetercseererceiee 12
7 Results and Discussion...

7.1 Analytical Parameters we . we

7.2 Comment on Strain TA1537 0... ccs ccceeeesceeseecsseeseesesesecenseseeseceseperaeteneeserens seenesuee 14
7.3 Evaluation of Dose Response and Increase over Spontaneous Revertants............0 15
74 Comparison of VIRGO Cigarette Types with TR4F ooo. ceeceescsesseeteesevenecsesersiee 15
8

9

10 Study Organization and Responsibilities «2.2.0.0... cccceecsseeeecenee 78
10.1 Study Organization

10.2 Responsibilities ..

11 Study Director Statement 0.0... ccc csecetseccseesessessecssecsseseesenesseens 80
12 Quality Assurance Statement... eescesseesseceeeenseessesetecsee Lee 84
13 Storage of Records and Materials... ccceesscssecsssssseesseeereeeee 82
14 Study Plan Amendments..............c.cccccccseesesesessessseessesssceeeeenseeeseee BS
15 REPEPENCES.. eee cece teeeeeetatecetscensecastecenectaseressesansenesstesstsesssetonses 84
16 ADbreviatiOns 2.0... eee cecete ee eenetsneseeseecseerseneesneneeesnesrtenseneneatens 86
Addendum

PRIORITY

LOOLLLP90Z